ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RENE Reneuron Group Plc

3.05
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.05 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 530k -5.41M -0.0946 -0.32 1.74M

ReNeuron Group plc Notice of Results (7909Z)

18/05/2023 7:00am

UK Regulatory


Reneuron (LSE:RENE)
Historical Stock Chart


From Mar 2023 to Mar 2024

Click Here for more Reneuron Charts.

TIDMRENE

RNS Number : 7909Z

ReNeuron Group plc

18 May 2023

ReNeuron Group plc

("ReNeuron" or the "Company")

Notice of Results

Investor presentation

ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , will announce its preliminary results for the year ended 31 March 2023 on Thursday 25 May 2023.

Investor Briefing

Management will also be hosting a live online presentation relating to the preliminary results via the Investor Meet Company platform at 9:30am BST on Thursday 25 May 2023. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here:

https://www.investormeetcompany.com/reneuron-group-plc/register-investor

Investors who already follow ReNeuron on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

ENDS

Enquiries:

 
 ReNeuron                                                www.reneuron.com/investors 
 Iain Ross, Executive Chairman                                      Via Walbrook PR 
 John Hawkins, Chief Financial Officer 
 
 Allenby Capital Limited (Nominated 
  Adviser and Broker)                                           +44 (0)20 3328 5656 
 James Reeve/George Payne/Dan Dearden-Williams 
  (Corporate Finance) 
 Stefano Aquilino (Sales & Corporate 
  Broking) 
 
 Walbrook PR (Media & Investor Relations)                       +44 (0)20 7933 8780 
 Paul McManus / Alice Woodings                           or reneuron@walbrookpr.com 
                                                  +44 (0)7980 541 893 / +44 (0)7407 
                                                                            804 654 
 

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX(TM) platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORQDLFFXELEBBE

(END) Dow Jones Newswires

May 18, 2023 02:00 ET (06:00 GMT)

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart

Your Recent History

Delayed Upgrade Clock